Ataxin-1 regulates epithelial-mesenchymal transition of cervical cancer cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, A-Ram | - |
dc.contributor.author | An, Hyoung-Tae | - |
dc.contributor.author | Ko, Jesang | - |
dc.contributor.author | Kang, Seongman | - |
dc.date.accessioned | 2021-09-03T08:25:27Z | - |
dc.date.available | 2021-09-03T08:25:27Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-03-14 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/84154 | - |
dc.description.abstract | The mutant form of the protein ataxin-1 (ATXN1) causes the neurodegenerative disease spinocerebellar ataxia type-1. Recently, ATXN1 was reported to enhance E-cadherin expression in the breast cancer cell line MCF-7, suggesting a potential association between ATXN1 and cancer development. In the present study, we discovered a novel mechanism through which ATXN1 regulates the epithelial-mesenchymal transition (EMT) of cancer cells. Hypoxia-induced upregulation of the Notch intracellular domain expression decreased ATXN1 expression via MDM2-associated ubiquitination and degradation. In cervical cancer cells, ATXN1 knockdown induced EMT by directly regulating Snail expression, leading to matrix metalloproteinase activation and the promotion of cell migration and invasion. These findings provide insights into a novel mechanism of tumorigenesis and will facilitate the development of new and more effective therapies for cancer. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.subject | NOTCH SIGNALING PATHWAY | - |
dc.subject | AXH DOMAIN | - |
dc.subject | MATRIX METALLOPROTEINASES | - |
dc.subject | HYPOXIA | - |
dc.subject | SNAIL | - |
dc.subject | TRANSCRIPTION | - |
dc.subject | EXPRESSION | - |
dc.subject | PHENOTYPE | - |
dc.subject | POLYGLUTAMINE | - |
dc.subject | PROGRESSION | - |
dc.title | Ataxin-1 regulates epithelial-mesenchymal transition of cervical cancer cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ko, Jesang | - |
dc.contributor.affiliatedAuthor | Kang, Seongman | - |
dc.identifier.doi | 10.18632/oncotarget.15319 | - |
dc.identifier.scopusid | 2-s2.0-85015252775 | - |
dc.identifier.wosid | 000396877500070 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.8, no.11, pp.18248 - 18259 | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 8 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 18248 | - |
dc.citation.endPage | 18259 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | NOTCH SIGNALING PATHWAY | - |
dc.subject.keywordPlus | AXH DOMAIN | - |
dc.subject.keywordPlus | MATRIX METALLOPROTEINASES | - |
dc.subject.keywordPlus | HYPOXIA | - |
dc.subject.keywordPlus | SNAIL | - |
dc.subject.keywordPlus | TRANSCRIPTION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | PHENOTYPE | - |
dc.subject.keywordPlus | POLYGLUTAMINE | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordAuthor | ATXN1 | - |
dc.subject.keywordAuthor | cervical cancer | - |
dc.subject.keywordAuthor | epithelial-mesenchymal transition | - |
dc.subject.keywordAuthor | notch intracellular domain | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.